Drugs / LNK001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07564232 | Jul 2026 → Jun 2031 expected | clear cell renal carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNK001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07564232 ↗ |
| Modality | Cell therapy | “Dual ENPP3/CAIX AND-gate CAR T Cell Therapy” NCT07564232 ↗ |
| Route | Other | “Given by infusion” NCT07564232 ↗ |
| Target | ENPP3 | “Dual ENPP3/CAIX AND-gate CAR T Cell Therapy” NCT07564232 ↗ |